Viridian Therapeutics, Inc. - Common Stock —— 资产负债表 (NASDAQ:VRDN) | MetaTrader

展开完整图表完整图表

Financials

概览声明统计

每季度年度

总资产 131.25 M203.71 M435.09 M490.42 M742.4 M899.42 M 负债总额 11.22 M15.99 M40.03 M48.4 M70.76 M177.25 M 权益总额 120.04 M187.72 M395.06 M442.02 M671.64 M722.17 M 负债及股东权益总额 131.25 M203.71 M435.09 M490.42 M742.4 M899.42 M 总债务 0———20.58 M84.18 M 净债务 -127.6 M———-697.02 M-790.52 M

新闻

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-05-09

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Can This Small Rival Take On Amgen's Eye Disease Blockbuster?

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-04-02

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics在Leerink会议上展望市场扩张

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion